Barclays PLC Intellia Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 292,795 shares of NTLA stock, worth $3.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

292,795

Previous 292,795 -0.0%

Holding current value

$3.57 Million

Previous $6.02 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$19.72 - $27.36 $1.76 Million - $2.45 Million	89,422 Added 43.97%	292,795 $6.02 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $361,921 - $492,083	18,078 Added 9.76%	203,373 $4.55 Million
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $3.95 Million - $5.45 Million	-166,035 Reduced 47.26%	185,295 $5.1 Million
Q4 2023 Feb 15, 2024	BUY	$23.16 - $32.34 $2.19 Million - $3.06 Million	94,704 Added 36.9%	351,330 $10.7 Million
Q3 2023 Nov 07, 2023	BUY	$31.62 - $45.78 $1.06 Million - $1.54 Million	33,558 Added 15.04%	256,626 $8.12 Million
Q2 2023 Aug 03, 2023	SELL	$34.58 - $46.03 $89,389 - $118,987	-2,585 Reduced 1.15%	223,068 $9.1 Million
Q1 2023 May 04, 2023	SELL	$33.3 - $44.82 $1.14 Million - $1.53 Million	-34,214 Reduced 13.17%	225,653 $8.41 Million
Q4 2022 Feb 13, 2023	BUY	$33.21 - $62.69 $2.5 Million - $4.72 Million	75,296 Added 40.8%	259,867 $9.07 Million
Q3 2022 Nov 03, 2022	BUY	$53.92 - $71.7 $4.19 Million - $5.57 Million	77,673 Added 72.66%	184,571 $10.3 Million
Q2 2022 Aug 12, 2022	BUY	$38.49 - $76.21 $233,287 - $461,908	6,061 Added 6.01%	106,898 $5.53 Million
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $2.21 Million - $4.51 Million	-37,922 Reduced 27.33%	100,837 $7.33 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $6.3 Million - $8.66 Million	62,574 Added 82.13%	138,759 $16.4 Million
Q3 2021 Nov 09, 2021	BUY	$132.37 - $176.78 $4.74 Million - $6.33 Million	35,823 Added 88.75%	76,185 $10.2 Million
Q2 2021 Aug 13, 2021	SELL	$60.88 - $161.91 $3.2 Million - $8.5 Million	-52,505 Reduced 56.54%	40,362 $6.53 Million
Q1 2021 May 13, 2021	BUY	$46.59 - $83.68 $3.53 Million - $6.34 Million	75,801 Added 444.16%	92,867 $7.45 Million
Q4 2020 Feb 11, 2021	SELL	$18.83 - $63.53 $244,658 - $825,445	-12,993 Reduced 43.22%	17,066 $928,000
Q3 2020 Nov 12, 2020	BUY	$17.47 - $24.93 $384 - $548	22 Added 0.07%	30,059 $597,000
Q2 2020 Aug 12, 2020	BUY	$11.14 - $22.87 $43,156 - $88,598	3,874 Added 14.81%	30,037 $632,000
Q1 2020 May 13, 2020	SELL	$9.44 - $15.58 $182,796 - $301,691	-19,364 Reduced 42.53%	26,163 $320,000
Q4 2019 Feb 10, 2020	BUY	$10.43 - $17.67 $271,065 - $459,225	25,989 Added 133.02%	45,527 $668,000
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $74,577 - $105,618	-5,706 Reduced 22.6%	19,538 $260,000
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $218,263 - $289,497	15,725 Added 165.2%	25,244 $413,000
Q1 2019 May 15, 2019	SELL	$12.79 - $17.62 $73,772 - $101,632	-5,768 Reduced 37.73%	9,519 $162,000
Q4 2018 Feb 14, 2019	SELL	$11.39 - $27.13 $11,595 - $27,618	-1,018 Reduced 6.24%	15,287 $209,000
Q3 2018 Nov 14, 2018	BUY	$25.78 - $32.6 $227,869 - $288,151	8,839 Added 118.39%	16,305 $466,000
Q2 2018 Aug 14, 2018	SELL	$20.02 - $30.79 $246,486 - $379,086	-12,312 Reduced 62.25%	7,466 $205,000
Q1 2018 May 15, 2018	BUY	$19.43 - $34.95 $203,684 - $366,380	10,483 Added 112.78%	19,778 $416,000
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $41,162 - $73,661	2,367 Added 34.17%	9,295 $179,000
Q3 2017 Nov 14, 2017	BUY	$15.16 - $25.75 $105,028 - $178,396	6,928	6,928 $172,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account